ArticleEchocardiography (Mount Kisco, N.Y.)2026
Age-Stratified Performance of the TAPSE/sPAP Ratio as a Marker of Right Ventricular-Pulmonary Arterial Coupling in Chronic Kidney Disease.
Article in Echocardiography (Mount Kisco, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRight ventricular (RV) dysfunction in chronic kidney disease (CKD) remains underrecognized. The tricuspid annular plane systolic excursion to systolic pulmonary artery pressure ratio (TAPSE/sPAP) reflects RV-pulmonary arterial coupling, but its relationship with CKD severity is unknown. To evaluate the association between TAPSE/sPAP ratio and CKD stage severity and assess age-related effect modification.
methodsThis cross-sectional study enrolled 120 participants: 40 patients with stage I-II CKD, 40 with stage III-IV CKD, and 40 healthy controls. All underwent echocardiography and nephrologist evaluation. Proportional odds regression models adjusted for cardiovascular risk factors evaluated the TAPSE/sPAP-CKD association. ROC analysis assessed discriminatory performance. Age-stratified analyses (<65 vs. ≥65 years) evaluated effect modification.
resultsTAPSE/sPAP ratio declined progressively across CKD stages (controls: 0.67 ± 0.11, stage I-II: 0.61 ± 0.13, stage III-IV: 0.53 ± 0.13 mm/mmHg; p < 0.01). Each 0.10-unit decrease was independently associated with advanced CKD (adjusted OR 2.08, 95% CI 1.49-2.89, p < 0.001). TAPSE/sPAP ratio achieved the highest AUC (0.734, 95% CI 0.625-0.833), outperforming TAPSE alone (AUC 0.615; DeLong p = 0.049), while statistically comparable to sPAP (AUC 0.715; DeLong p = 0.400). Age-stratified analysis revealed excellent performance in patients <65 years (AUC 0.819, sensitivity 78.6%, specificity 86.8%) but limited utility in those ≥65 years (AUC 0.579; p = 0.015). Random forest analysis identified age (35.8%) and TAPSE/sPAP (22.0%) as dominant predictors.
conclusionsTAPSE/sPAP ratio is an independent marker of CKD severity enabling non-invasive detection of RV-PA uncoupling, with excellent discriminatory performance in younger but limited utility in older patients, suggesting that age-specific interpretation and integration with renal biomarkers are recommended.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.